Visual Abstract
Intro: In 2016 the FDA changed metformin’s label to allow initiation at estimated glomerular filtration rate levels of ≥ 45 mL/min/1.73 m2. We sought to determine trends of incident metformin for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) from 2010-2018.
Methods: We assessed trends of new metformin prescriptions in treatment naïve patients with T2DM and CKD from the Veterans Affairs from 2010-2018. Incidence was calculated as the number of new metformin prescriptions per 1,000 eligible patients.
Results: A total of 616,670 patients were eligible. Patients had a mean age of 68 (SD 11.1), 95.8% were male, and 72.2% were white. Figure 1 displays trends in the total cohort. Figure 2 displays trends by CKD stage.
Discussion: There was increased trend in new metformin prescriptions predominately in stages 3a and 3b.
C. A. Alvarez: None. A. Perkins: None. L. Gregg: None. E. Mortensen: None.
National Institutes of Health (K08DK101602)